Bill Sponsor
House Bill 1409
115th Congress(2017-2018)
Cancer Drug Parity Act of 2017
Introduced
Introduced
Introduced in House on Mar 7, 2017
Overview
Text
Introduced
Mar 7, 2017
Latest Action
Mar 17, 2017
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1409
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
New Jersey
Republican
Alaska
Republican
Arizona
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Republican
Colorado
Republican
Colorado
Democrat
Connecticut
Democrat
Connecticut
Democrat
Connecticut
Democrat
District of Columbia
Republican
Florida
Democrat
Florida
Republican
Florida
Republican
Georgia
Democrat
Georgia
Republican
Georgia
Democrat
Illinois
Democrat
Illinois
Democrat
Illinois
Republican
Illinois
Democrat
Kentucky
Republican
Louisiana
Democrat
Maryland
Democrat
Maryland
Democrat
Massachusetts
Democrat
Massachusetts
Democrat
Massachusetts
Democrat
Massachusetts
Democrat
Massachusetts
Democrat
Massachusetts
Democrat
Michigan
Republican
Michigan
Republican
Michigan
Republican
Michigan
Republican
Michigan
Republican
Michigan
Democrat
Minnesota
Republican
Mississippi
Republican
Mississippi
Republican
Mississippi
Republican
Missouri
Republican
Nebraska
Democrat
New Hampshire
Republican
New Jersey
Republican
New Jersey
Democrat
New Mexico
Republican
New York
Democrat
New York
Republican
New York
Democrat
New York
Republican
New York
Democrat
New York
Democrat
New York
Democrat
North Carolina
Democrat
North Carolina
Republican
North Carolina
Republican
North Carolina
Republican
North Dakota
Democrat
Pennsylvania
Democrat
Pennsylvania
Republican
Pennsylvania
Republican
Pennsylvania
Democrat
Pennsylvania
Republican
Pennsylvania
Republican
Pennsylvania
Democrat
Pennsylvania
Democrat
Pennsylvania
Republican
Pennsylvania
Republican
Pennsylvania
Democrat
Rhode Island
Republican
South Carolina
Republican
South Carolina
Republican
Tennessee
Democrat
Tennessee
Republican
Texas
Republican
Virginia
Republican
Washington
Democrat
Washington
Democrat
Washington
Republican
West Virginia
Democrat
Wisconsin
Republican
Wisconsin
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Cancer Drug Coverage Act of 2017

This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Text (1)
March 7, 2017
Actions (3)
03/17/2017
Referred to the Subcommittee on Health.
03/07/2017
Referred to the House Committee on Energy and Commerce.
03/07/2017
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:35:43 PM